Sanofi SA (EPA:SAN) has been assigned a consensus recommendation of “Hold” from the seventeen ratings firms that are covering the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is €87.13 ($96.81).
A number of equities analysts have weighed in on the stock. Jefferies Group set a €76.00 ($84.44) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Tuesday, September 13th. Kepler Capital Markets set a €91.00 ($101.11) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research report on Thursday, July 7th. Independent Research GmbH set a €77.00 ($85.56) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Thursday, June 30th. Berenberg Bank set a €93.00 ($103.33) target price on shares of Sanofi SA and gave the company a “buy” rating in a research note on Thursday, September 8th. Finally, BNP Paribas set a €78.00 ($86.67) target price on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Wednesday, September 14th.
Shares of Sanofi SA (EPA:SAN) opened at 68.41 on Friday. Sanofi SA has a one year low of €62.50 and a one year high of €93.82. The stock has a market cap of €88.04 billion and a price-to-earnings ratio of 21.27. The firm has a 50-day moving average price of €25.95 and a 200-day moving average price of €25.75.
Sanofi SA Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.